
    
      OBJECTIVES:

      I. Evaluate the feasibility of administering Rosuvastatin to breast cancer patients
      undergoing treatment with anthracyclines, paclitaxel, cyclophosphamide, and trastuzumab for
      breast cancer.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      Arm I: Patients receive rosuvastatin orally (PO) once daily for 3 months in the absence of
      disease progression or unacceptable toxicity.

      Arm II: Patients receive placebo PO once daily for 3 months in the absence of disease
      progression or unacceptable toxicity.
    
  